"Brightening the future of people facing challenges of cancers."
Solasia has been developing a wide range of products varying from pharmaceuticals for cancer therapy to supportive care for adverse event of drugs.
Development Status
PRODUCTS
| PIPELINES | INDICATION | AREA | PRE- CLINICAL |
CLINIAL STUDY | NDA | APPROVAL /LAUNCH |
PROGRESS | PARTNER | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PHASE 1 | PHASE 2 | PHASE 3 | ||||||||
|
Sancuso®（SP-01） MORE INFO |
Chemotherapy Induced Nausea and Vomiting (CINV) | China |
|
|
|
|
|
|
Launched in 2019 | Solasia sales force: Beijing, Shanghai, Guangzhou
Lee’s Pharma: |
|
episil® oral liquid（SP-03） MORE INFO |
Pain associated oral mucositis [Medical Device] | Japan |
|
|
|
|
Launched in 2018 | Meiji Seika Pharma: Japan
Solasia sales force: Beijing, Shanghai, Guangzhou
Lee’s Pharma:
Synex： |
||
| China |
|
|
|
|
Launched in 2019 | |||||
| South Korea |
|
|
|
|
Launched in 2020 | |||||
PIPELINES
| PIPELINES | TARGET INDICATION |
AREA | PRE- CLINICAL |
CLINIAL STUDY | NDA | APPROVAL /LAUNCH |
PROGRESS | PARTNER | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PHASE 1 | PHASE 2 | PHASE 3 | ||||||||
|
SP-02 MORE INFO |
Peripheral T-Cell Lymphoma (PTCL) | Japan |
|
|
|
|
|
|
Submitted NDA | Nippon Kayaku:
|
| South Korea, Taiwan, Hong Kong |
|
|
|
|
|
|
Pivotal PII study completion, preparation for NDA filing | |||
| China |
|
|
|
|
|
|
Phase II/III, preparation | |||
| US |
|
|
|
|
|
|
Phase IIA, completion | |||
| EU |
|
|
|
|
|
|
Phase II/III, preparation | |||
|
SP-04 MORE INFO |
Chemotherapy Induced Peripheral Neuropathy (CIPN) | Japan etc. |
|
|
|
|
|
|
Pre-clinical study in taxane-induced peripheral neuropathy | Maruho: |
|
SP-05 MORE INFO |
Colorectal Cancer (CRC) | Japan |
|
|
|
|
|
|
Global Phase III study | ー |
New Pipeline Candidates
RECQL1-siRNA Project
Nucleic acid drug candidate for peritoneal metastases (disseminated metastases developing in the peritoneum): Option agreement for in-license of worldwide rights with GeneCare Research Institute Co., Ltd.
RNA Editing Technology Project
New drug candidates for rare disease and/or oncology based on RNA editing technology utilizing pentatricopeptide repeat (PPR) protein platform technology: Joint R&D agreement with EditForce Inc.